D

Day One Biopharmaceuticals Inc
NASDAQ:DAWN

Watchlist Manager
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Watchlist
Price: 12.69 USD -0.78% Market Closed
Market Cap: 1.3B USD
Have any thoughts about
Day One Biopharmaceuticals Inc?
Write Note

Day One Biopharmaceuticals Inc
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Day One Biopharmaceuticals Inc
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
D
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Total Assets
$376m
CAGR 3-Years
102%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Assets
$143.4B
CAGR 3-Years
-1%
CAGR 5-Years
19%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Total Assets
$54.5B
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Assets
$90.9B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Assets
$22.2B
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Assets
$37.4B
CAGR 3-Years
17%
CAGR 5-Years
22%
CAGR 10-Years
26%
No Stocks Found

Day One Biopharmaceuticals Inc
Glance View

Market Cap
1.3B USD
Industry
Biotechnology

Day One Biopharmaceuticals Inc. emerged on the healthcare scene with a mission deeply rooted in a poignant reality: the need for tailored cancer treatments for children. Named symbolically to reflect the fresh start they aspire to offer to young patients, Day One focuses on developing and commercializing targeted therapies specifically for pediatric cancer, a field historically overlooked by the larger pharmaceutical industry. The company employs innovative drug development strategies, utilizing molecular targeted therapy—a precise approach that zeroes in on cancer cells while sparing healthy ones. This methodology not only underscores their commitment to efficacy and safety but also positions them as pioneers in an area rife with unmet medical needs. Fundamentally, the company generates its revenue through the successful commercialization of its therapies. It channels resources into robust clinical trials to demonstrate the efficacy and safety of its drugs, seeking regulatory approvals as key milestones. Licensing deals also play a crucial role in its business model, as partnerships with larger pharmaceutical firms enable Day One to expand its reach and scale. This strategic blending of in-house development and external alliances allows Day One to navigate the complex biopharmaceutical landscape efficiently, driving both innovation and financial sustainability. As they continue to advance their pipeline, the company aims to reshape pediatric oncology, demonstrating that profitable ventures can indeed be built around noble societal missions.

DAWN Intrinsic Value
13.54 USD
Undervaluation 6%
Intrinsic Value
Price
D

See Also

What is Day One Biopharmaceuticals Inc's Total Assets?
Total Assets
376m USD

Based on the financial report for Dec 31, 2023, Day One Biopharmaceuticals Inc's Total Assets amounts to 376m USD.

What is Day One Biopharmaceuticals Inc's Total Assets growth rate?
Total Assets CAGR 3Y
102%

Over the last year, the Total Assets growth was 8%. The average annual Total Assets growth rates for Day One Biopharmaceuticals Inc have been 102% over the past three years .

Back to Top